Filing Overview
MoonLake Immunotherapeutics filed a Form 8-K dated June 7, 2023, reporting the results of its 2023 Annual General Meeting of Shareholders. The meeting was held on June 7, 2023, and the record date was April 13, 2023. As of the record date, 43,654,455 Class A ordinary shares and 9,046,656 Class C ordinary shares were entitled to vote.
Annual Meeting Results
- Director elections: Class I nominees Dr. Kara Lassen and Spike Loy were elected.
- Dr. Kara Lassen: 37,996,564 votes for, 93,222 votes withheld, and 3,496,781 broker non-votes.
- Spike Loy: 37,728,807 votes for, 360,979 votes withheld, and 3,496,781 broker non-votes.
- Independent auditor: Shareholders ratified Baker Tilly US, LLP as the Company’s independent auditor, with 41,585,151 votes for, 366 against, 1,050 abstentions, and no broker non-votes.
Financial Metrics and Material Changes
This 8-K does not report revenue, profit, cash flow, margins, debt, liquidity, operating guidance, or other financial metrics. The filing text does not provide a clear financial comparison with a prior period or identify material financial changes.
Outlook, Risks, and Unusual Items
The filing contains no new guidance, outlook, management commentary, risk disclosures, contingencies, or unusual financial items. Its subject is limited to shareholder voting results.
Investor Verification Items
- Verify the election of Dr. Kara Lassen and Spike Loy to the Class I director positions.
- Verify shareholder ratification of Baker Tilly US, LLP as independent auditor.
- Review the Company’s other filings for current financial condition, cash runway, clinical-program updates, guidance, and risk factors.